Search
Barclays Miami: Teva CEO Richard Francis talks about the company's emphasis on developing innovative medicines - including two recent financial deals to speed up development of IL-15 and TL1A
He discusses the company's third year in a row of revenue growth, and the new products that have helped Teva get there. Plus, a potential near-term approval for a monthly dosed schizophrenia product, and the lates on IL-15 and TL1A.
3 hours ago
At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech...
May 29, 2025
SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation
He describes how he believes the TL1A compares to others in the field, other programs in the company's innovation pipeline, and the...
Jan 13, 2025
.png){kind=logo}
